Wilmer Cutler Pickering Hale and Dorr advised MicroStrategy Incorporated in the offering, and Davis Polk & Wardwell advised Barclays Capital, Inc., as representatives of the initial...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale advised MicroStrategy Incorporated, and Davis Polk advised the Agents on the offering. MicroStrategy Incorporated (MicroStrategy) (Nasdaq: MSTR) announced the company’s new at-the-market...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised MicroStrategy Incorporated in the offering, and Davis Polk & Wardwell advised the representative of the several initial purchasers. MicroStrategy...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Medtronic, Inc. in the offering. Medtronic plc (NYSE: MDT) announced it closed its €3 billion public offering, consisting of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented MicroStrategy® Incorporated in the offering, and Davis Polk & Wardwell advised the representative of the initial purchasers. MicroStrategy Incorporated...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Arvinas, Inc. on the transaction. Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas”) announced that it entered into a securities purchase agreement with a...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Symphony on the deal while Wilmer Cutler Pickering Hale and Dorr represented Cloud9 Technologies. Symphony announced its acquisition of Cloud9 Technologies. Symphony is...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Cue Health Inc. on the deal. Cue Health Inc., a health technology company, announced the closing of its $235...
You must be a Standard 1 Year member to access this content.
